In light of the pandemic, the Life Science Industry is changing. One of the positive developments: The industry is moving faster. The necessity of developing diagnostics, therapeutics, and vaccines against this novel viral threat quickly generates a steep learning curve for all of us.
In this episode, I am talking with Peter Llewellyn-Davies, CEO of Apeiron Biologics, how he and his team have set up a clinical phase 2 trial and a 40 million Euro financing round in less than eight weeks.
Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Peter Llewellyn-Davies (https://www.linkedin.com/in/peterld/)
Companies:
Apeiron Biologics (https://www.linkedin.com/company/apeiron-biologics/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g
Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)
The LSG2G Partners
Experts in Life Science
#20: How to close a 40 million Euro financing round in less than 8 weeks